These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35890333)

  • 1. Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.
    Dri DA; Gaucci E; Torrieri I; Carafa M; Marianecci C; Gramaglia D
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials.
    Dri DA; Marianecci C; Carafa M; Gaucci E; Gramaglia D
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office.
    Dri DA; Praticò G; Gaucci E; Marianecci C; Gramaglia D
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Authorization of COVID-19 clinical trials: lessons from 2 years of experience of a national competent authority.
    Vignot S; Dhanani A; Sainte-Marie I; de Ligniville Lajavardi L; Even G; Echemann M; Hulin N; Ménoret C; Maison P; Ratignier-Carbonneil C
    Front Pharmacol; 2022; 13():972660. PubMed ID: 36046816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
    Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
    Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
    Chowdhury N
    Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
    Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA
    Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Machine Learning in Centralized Authorization Process of Nanomedicines in European Union.
    Santana R; Onieva E; Zuluaga R; Duardo-Sánchez A; Gañán P
    Curr Top Med Chem; 2021; 21(9):828-838. PubMed ID: 33745436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Situation analysis on the regulation of nanomedicines in Southern Africa.
    Mudyiwenyama LG; Khoza S; Dube A
    Front Med (Lausanne); 2023; 10():1098830. PubMed ID: 37153083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
    Ziegele B; Dahl L; Müller AT
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Considerations on the use of Machine Learning based tools in Clinical Trials.
    Massella M; Dri DA; Gramaglia D
    Health Technol (Berl); 2022; 12(6):1085-1096. PubMed ID: 36373014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.